Fed Governor Cook sues Trump over firing attempt
HENDERSON, Nev. - VolitionRx Limited (NYSE AMERICAN: VNRX), a $58 million market cap diagnostic company showing 64% revenue growth in the last twelve months according to InvestingPro data, reported Thursday that a peer-reviewed clinical study suggests its Nu.Q H3.1 biomarker could potentially inform clinical care for critically ill patients by assessing sepsis, organ failure and inflammatory responses.
The study, involving 1,713 intensive care unit patients, examined the relationship between H3.1 nucleosome concentrations and clinical outcomes. Researchers collected plasma samples on days 0, 2, and 4, totaling 3,671 samples.
According to the publication, patients with acute kidney injury, disseminated intravascular coagulation, and acute respiratory distress syndrome showed significantly higher Nu.Q H3.1 levels compared to those without these conditions.
Dr. Andrew Retter, Chief Medical Officer at Volition, described the biomarker as "clinically meaningful" and "biologically specific" for measuring NETosis, a cellular process related to immune response.
Lieuwe D.J. Bos, PhD, Principal Investigator at Amsterdam University Medical Center and senior author of the study, stated that plasma nucleosomes represented by H3.1 concentration "are associated with the presence of sepsis, the severity of organ dysfunction, and a hyperinflammatory host response."
The study positions the assay not as a traditional diagnostic tool but as a potential instrument for prognostic assessment and therapeutic monitoring. While the company shows promising technological developments, InvestingPro analysis indicates the company is currently burning through cash rapidly, with a current ratio of 0.4 suggesting potential liquidity challenges ahead.
Volition, a multi-national epigenetics company, focuses on developing blood tests for disease detection and monitoring. The company conducts research primarily in Belgium, with additional facilities in the United States and London.
The information is based on a company press release statement.
In other recent news, VolitionRX Limited reported its first-quarter 2025 financial results, revealing a larger-than-expected loss per share and a revenue shortfall. The company posted an earnings per share (EPS) of -$0.06, missing the forecasted -$0.04, and revenue of $250,000, significantly below the expected $1.31 million. Despite these financial misses, VolitionRX is focusing on reducing operational costs, which declined by 35% from the previous year, and advancing its Nu.Q platform in the human diagnostic market. Jones Trading initiated coverage of VolitionRX with a Buy rating and set a price target of $3.00, citing potential growth opportunities and strategic partnerships in the human health arena. Meanwhile, Benchmark maintained a Hold rating, highlighting the company’s focus on licensing agreements and expanding its veterinary testing division. VolitionRX is also working on multiple licensing agreements in the human diagnostic space, with discussions underway with several pharmaceutical companies. The company aims to be cash neutral by the end of 2025 and is pursuing various initiatives to bolster its market presence and revenue.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.